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(57) ABSTRACT 
Disclosed herein are therapies for treating or preventing reoc-
currence of cancer. The therapies involved inhibition of 
LIMKl in conjunction with AurKA inhibition. Specifically 
exemplified herein is the administration of an AurKA inhibi-
tor in conjunction with a LIMKl RNA interfering molecule. 
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FIG. 2 LIMK1 Constructs 
PDZ Kinase 
Full length (LIMK), constitutively active phosphomimic (LIMKcA), LIM-
domain only (LIMKL0 ), and kinase-domain only (LIMKK0 ) LIMK1 
constructs were cloned into the pCMV14 vector used for expression 
in RWPE1 cells. 
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Levels of pAurKA in PC3 Cells Treated with 
LIMK1 shRNA 
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A: PC3 cells were 
transfected with either 
LIMK1 or control sh RNA. In 
control shRNA transfected 
cells, distinct localization of 
pAurKA (green) at the 
spindle poles (red) could be 
noted. In LIMK1 shRNA 
treated cells, alpha-tubulin 
staining (red) showed 
disorganized spindle 
structure. Diffused 
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Cell Survival After Treatment 










U.S. Patent Dec. 16, 2014 Sheet 15 of 17 US 8,911,725 B2 










£0 =i* PC3 
SS 
'W 
{!.001uM O.D1uM O.luM 
A 
24h Treatment PC3 tlMKl Knockdown 
li:'>C! 
<t % 
2 90 a:: .c ~:~ 
"' 0 m 
~ 75 
{) "/'J Sl PO-C;:mt 
v t;;i; 
¢ BO Sl PCs-shRNA 
~ SS 
50 
{J,001uM G.01 uM 0.1uM 
MLNS2l7 
B 








¢ 7\3 ssPC:H1M$0 
~ £5 
t'O Sl PC'l·l:<hib 
5S 
:;ci 




U.S. Patent Dec. 16, 2014 Sheet 16of17 US 8,911,725 B2 
4Sh Treatment PC3 LIMKl Knockdown 
1{J{l.Q 
e 9${) .. 900 c: 
0 85 0 
v Bi.W 
~ 
~ 75J) .. 
"' 7!J.t1 & F 65.~ ... 60.G 
0 ss.n '$. 
:~o o 
0.G01uM 0.01 uM G.1uM 
MLf\18237 
'········································································································································~ A 













Ohr :Mhr 4Shr 
B 





6ti .t:: !:::DMSO 







Ohr 24hr 4-Bhr 
c 
FIG.10 
U.S. Patent Dec. 16, 2014 Sheet 17 of 17 US 8,911,725 B2 














Ohr 24hr 48nr 
FIG. 11 
US 8,911,725 B2 
1 
CO-TARGETING OF AURORA A KINASE 
AND LIM KINASE 1 FOR CANCER THERAPY 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims is related to U.S. Provisional 
Application No. 61/357,652; filed Jun. 23, 2010. Priority to 
this application is claimed under 35 USC 119 and is incorpo- 10 
rated herein by reference in its entirety. 
SEQUENCE LISTING 
The instant application contains a Sequence Listing which 15 
has been submitted in ASCII format via EFS-Web and is 
2 
FIG. 4B shows that incubation of Aurora A with LIMKl 
resulted in phosphorylation ofLIMKl at T508. 
FIG. 5 Dual label immunofluorescence analysis shows that 
LIMKl (red) and phospho AurKA (pAurKA) (green) colo-
calize to the centrosomes, which suggests their functional 
cooperativity 
FIG. 6 PC3 cells were transfected with LIMKl shRNA or 
control shRNA and the levels of LIMKl and pAurKA were 
detected by western blotting using anti-LIMKl or anti phos-
pho-AurKA antibodies. GAPDH was used as the loading 
control. The ratio of pAurKA to GAPDH levels was deter-
mined by densitometry (left panel). 
FIG. 7 A: PC3 cells were transfected with either LIMKl or 
hereby incorporated by reference in its entirety. Said ASCII 
copy, created on Sep. 23, 2011, is named 10669079.txt and is 
505 bytes in size. 
control shRNA. In control shRNA transfected cells, distinct 
localization of pAurKA (green) at the spindle poles (red) 
could be noted. In LIMKl shRNA treated cells, alpha-tubulin 
staining (red) showed disorganized spindle structure. 
2° FIG. 7B: Knockdown ofLIMKl increased the number of 
BACKGROUND 
Despite recent advances in development of improved can-
cer therapeutics one of the many clinical challenges is that 
25 
patients often show resistance to cancer drugs. This invention 
provides evidence that an alternate method of treatment of 
cancer could be adopted for improved efficacy of existing 
therapies and/or treatment of drug resistant cancers. This 30 
study describes a novel functional relationship between two 
proteins that regulate proliferation of cells. Because these 
proteins are involved in cell growth, the amounts of these 
proteins are tightly regulated in normal cells however in can- 35 
cer cells, abnormally increased amounts of these proteins are 
noted. One of the common methods for controlling abnormal 
growth of cancer cells is to inhibit production of these pro-
teins. However, there are incidences of frequent development 
of resistance to the chemotherapeutic agents upon prolonged 40 
treatment, which sometimes is necessary to destroy all the 
cancer cells in the body. 
Aurora A kinase (AurKA), a serine/threonine kinase and a 
member of Aurora kinase family, plays an essential role in 45 
proper mitotic function. Full activation of AurKA requires 
binding to the LIM domain containing protein. Earlier studies 
abnormal spindles in PC3 cells. PC3 cells were transfected 
with either LIMKl or control shRNA and spindle abnormali-
ties were quantified by counting 50 cells per treatment. 
FIG. 8. Treatment with Aurora A kinase inhibitor 
MLN8237 resulted in Mislocaliation of phosphoLIMKl and 
phosphoAurK A: PC3 and RWPEl cells were treated with 
MLN8237 (0.01 uM) for 24 hr or the vehicle (DMSO) for 72 
hr. Immunofluorescence analysis showed that treatment with 
MLN8237 caused mislocalization of pAurKA (green) and 
improper spindle morphology (alpha-tubulin) (red). In addi-
tion, diffused staining and mislocalization of pLIMKl 
(green) and centrin (red) in the nucleus were noted. The 
vehicle control cells showed colocalization of pLIMKl with 
centrin to the centrosomes (red). Aurora A Inhibition 
Increased the Levels of phospho-Histone H3 suggesting 
mitotic arrest (B). Western blot analysis of nuclear extracts 
from PC3 cells treated with MLN8237 (0.01 uM). 1-tubulin 
staining was used as the loading control. Aurora A Inhibition 
Decreased Cell Survival (C). PC3 and RWPEl cells were 
treated with MLN8237 (0.01 uM) MLN8237 for 24, 48, and 
72 hr and cell viability was measured by MTT Assay. 
FIG. 9 pertains to graphs presenting evidencing showing 
that LIMKl inhibition potentiates the sensitivity of cells to an 
AurKA inhibitor. 
have indicated a possible role of a LIM domain containing FIG. 10 pertains to graphs presenting additional evidenc-
serine/threonine and tyrosine kinase, LIM kinase 1 (LIMKl ), 
50 
ing showing that LIMKl inhibition potentiates the sensitivity 
in the mitotic process. of cells to an AurKA inhibitor. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 11 pertains to graphs presenting further evidencing 
showing that LIMKl inhibition potentiates the sensitivity of 
cells to an AurKA inhibitor. 
FIG. 1 shows a Western blot analysis showing expression 55 
of AurKA and LIMKl in BPH and BPHL cells. DETAILED DESCRIPTION 
FIG. 2 shows a diagram of Full length (LIMK), constitu-
tively active phosphomimic (LIMKCA), LIM-domain only 
(LIMKLD), and kinase-domain only (LIMKKD) LIMKl 
constructs. 
FIG. 3 A: shows results of a Pull-down assay demonstrat-
ing an association between LIMK and Aurora A. 
FIG. 3B: shows western blot results demonstrating that 
Aurora A interacts with LIMKl in vivo. 
FIG. 4 A: shows results of in vitro kinase assays demon-
strating Aurora A phosphorylates inactive LIMKl in vitro. 
Disclosed herein are inventive embodiments that are based 
on the discovery that inhibition of LIMKl in conjunction 
60 AurKA inhibitors potentiates the sensitivity of cells to the 
AurKA inhibitors. Accordingly, administration of anAurKA 
inhibitor together with LIMKl inhibition will enable the use 
oflesser amounts of individual inhibitor while obtaining the 
65 same effect. Further, this will minimize the side effects of 
individual drugs and possibly delay the process of develop-
ment of drug-resistant cancers. 
US 8,911,725 B2 
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Presented herein is evidence demonstrating a novel func-
tional association between AurKA and LIMKl in cancer 
cells, e.g., in prostate cancer cells. Overexpression ofLIMKl 
in benign prostate hyperplasia (BPH-1) cells resulted in 
increased expression of AurKA. Immunofluorescence analy-
4 
identify mRNA molecules that are at least partially comple-
mentary to the incorporated siRNA strand, and then cleaves 
these target mRNAs or inhibits their translation. Therefore, 
the siRNA strand that is incorporated into RISC is known as 
the guide strand or the antisense strand. The other siRNA 
strand, known as the passenger strand or the sense strand, is 
eliminated from the siRNA and is at least partially homolo-
gous to the target mRNA. Those of skill in the art will recog-
10 nize that, in principle, either strand of an siRNA can be 
incorporated into RISC and function as a guide strand. How-
ever, siRNA design (e.g., decreased siRNA duplex stability at 
the 5' end of the desired guide strand) can favor incorporation 
sis showed colocalization of phosphorylated LIMKl with 
AurKA to the centrosomes in PC3 prostate cancer cells, 
which naturally overexpress LIMKl. shRNA mediated 
knockdown ofLIMKl decreased the level of phosphorylated 
AurkA and caused disorganized spindle morphology with 
phosphorylated AurKA localized to multiple spindle poles. 
Immunoprecipitation and pull-down assays showed that 
LIMKl and AurKA associate in a complex. Interaction 
assays using deletion mutants ofLIMKl showed thatAurKA 15 
binds to the LIM domains and the kinase domain indepen-
dently in addition to the full-length LIMKl. LIMKl acts as a 
substrate of AurKA and inhibition of AurKA activity resulted 
in mislocalization of phosphoLIMKl and the centrosomal 20 
protein centrin. 
The present disclosure indicates for the first time that 
AurKA and LIMKl are functionally cooperating during 
mitosis. Overexpression of AurKA has been noted in a variety 
of the desired guide strand into RISC. 
The antisense strand of an siRNA is the active guiding 
agent of the siRNA in that the antisense strand is incorporated 
into RISC, thus allowing RISC to identify target mRNAs with 
at least partial complementarity to the antisense siRNA strand 
for cleavage or translational repression. RISC-related cleav-
age of mRNAs having a sequence at least partially comple-
mentary to the guide strand leads to a decrease in the steady 
state level of that mRNA and of the corresponding protein 
encoded by this mRNA. Alternatively, RISC can also 
decrease expression of the corresponding protein via transla-
tional repression without cleavage of the target mRNA. 
of cancers including prostate cancer and currently, small mo!- 25 
ecule inhibitors targeting AurKA are undergoing clinical tri-
als. This study provides evidence that targeted inhibition of 
LIMKl has the added benefit of functional inhibition of 
The GenBank database provides the DNA sequence for 
LIMKl as accession no. NM_002314. Equivalents of the 
30 
above cited LIMkl mRNA sequence are alternative splice AurKA. 
Aurora kinase A inhibitors are currently undergoing phase forms, allelic forms, isozymes, or a cognate thereof. A cog-
nate is a LIMKl mRNA from another manimalian species 
that is homologous to the cited human form (i.e., an ortholog). 
The GenBank database provides the DNA sequence for 
I and II clinical trials for cancer treatment but not all patients 
respond to this drug as resistance to kinase inhibitors devel-
ops frequently. The results of the evidence herein also pro-
vides evidence that targeted inhibition of Aurora A kinase 
may have the added benefit of also inhibiting LIMKl, and 
vice versa. 
Accordingly, A) combination therapy of AurKA and 
LIMKl inhibitors will improve effectiveness of AurKA 
inhibitors and B) inhibitors of LIMKl function may be used 
for patients showing resistance to AurKA inhibitors. Further-
more, other inventive embodiments relate to the development 
35 AurKA as accession no NM_l9843. Equivalents of the 
above cited AurKA mRNA sequence are alternative splice 
forms, allelic forms, isozymes, or a cognate thereof. A cog-
nate AurKA mRNA from another mammalian species that is 
40 
homologous to the cited human form. 
The term "siRNA" as used herein refers to a double-
of inhibitors of LIMKl and use for combination therapy with 
AurKA inhibitors or use singly for AurKA resistant cancers. 45 
In one embodiment, a single interfering RNA targeting 
LIMkl or AurKA mRNA is administered to decrease respec-
tive levels of each. In other embodiments, two or more inter-
fering RNAs targeting the LIMKl and/or AurKA mRNA are 
50 
stranded interfering RNA unless otherwise noted. Typically, 
an siRNA of the invention is a double-stranded nucleic acid 
molecule comprising two nucleotide strands, each strand hav-
ing about 19 to about 28 nucleotides (i.e. about 19, 20, 21, 22, 
23, 24, 25, 26, 27, or 28 nucleotides). The phrase "interfering 
RNA having a length of 19 to 49 nucleotides" when referring 
to a double-stranded interfering RNA means that the anti-
sense and sense strands independently have a length of about 
19 to about 49 nucleotides, including interfering RNA mol-
ecules where the sense and antisense strands are connected by 
a linker molecule. 
administered to decrease LIMKl and/or AurKA levels. In 
certain embodiments, interfering RNA targeting LIMKl and/ 
or interfering RNA targeting AurKA are administered to the 
subject sequentially or concurrently, thereby treating a related 
cancer. 
In addition to siRNA molecules, other interfering RNA 
55 molecules and RNA-like molecules can interact with RISC 
RNA interference (RNAi) is a process by which double-
stranded RNA (dsRNA) is used to silence gene expression. 
While not wanting to be bound by theory, RNAi begins with 
the cleavage of longer dsRNAs into small interfering RNAs 
(siRNAs) by an RNaseIII-like enzyme, dicer. SiRNAs are 60 
dsRNAs that are usually about 19 to 28 nucleotides, or 20 to 
25 nucleotides, or 21 to 22 nucleotides in length and often 
contain 2-nucleotide 3' overhangs, and 5' phosphate and 3' 
hydroxyl termini. One strand of the siRNA is incorporated 65 
into a ribonucleoprotein complex known as the RNA-induced 
silencing complex (RISC). RISC uses this siRNA strand to 
and silence gene expression. Examples of other interfering 
RNA molecules that can interact with RISC include short 
hairpin RNAs (shRNAs), single-stranded siRNAs, microR-
NAs (miRNAs), and dicer-substrate 27-mer duplexes. 
Examples of RNA-like molecules that can interact with RISC 
include siRNA, single-stranded siRNA, microRNA, and 
shRNA molecules containing one or more chemically modi-
fied nucleotides, one or more non-nucleotides, one or more 
deoxyribonucleotides, and/or one or more non-phosphodi-
ester linkages. All RNA or RNA-like molecules that can 
interact with RISC and participate in RISC-related changes in 
US 8,911,725 B2 
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gene expression are referred to herein as "interfering RNAs" 
or "interfering RNA molecules." SiRNAs, single-stranded 
siRNAs, shRNAs, miRNAs, and dicer-substrate 27-mer 
duplexes are, therefore, subsets of "interfering RNAs" or 
"interfering RNA molecules." 
6 
are then tested in vitro by transfection of cells expressing the 
target mRNA followed by assessment of knockdown as 
described herein. The interfering RNAs can be further evalu-
ated in vivo using animal models as described herein. 
Techniques for selecting target sequences for siRNAs are 
provided, for example, by Tuschl, T. et al., "The siRNA User 
Guide," revised May 6, 2004, available on the Rockefeller 
University web site; by Technical Bulletin #506, "siRNA 
10 Design Guidelines," Ambion Inc. atAmbion's web site; and 
Single-stranded interfering RNA has been found to effect 
mRNA silencing, albeit less efficiently than double-stranded 
RNA. Therefore, embodiments of the present invention also 
provide for administration of a single-stranded interfering 
RNA that has a region of at least near-perfect contiguous 
complementarity with a portion of the LIMKl mRNA or 
AurKA mRNA. The single-stranded interfering RNA has a 
length of about 19 to about 49 nucleotides as for the double-
stranded interfering RNA cited above. The single-stranded 15 
interfering RNA has a 5' phosphate or is phosphorylated in 
situ or in vivo at the 5' position. The term "5' phosphorylated" 
by other web-based design tools at, for example, the Invitro-
gen, Dharmacon, Integrated DNA Technologies, Genscript, 
or Proligo web sites. Initial search parameters can include 
G/C contents between 35% and 55% and siRNA lengths 
between 19 and 27 nucleotides. The target sequence may be 
located in the coding region or in the 5' or 3' untranslated 
regions of the mRNA. The target sequences can be used to is used to describe, for example, polynucleotides or oligo-
nucleotides having a phosphate group attached via ester link-
age to the CS hydroxyl of the sugar (e.g., ribose, deoxyribose, 
or an analog of same) at the 5' end of the polynucleotide or 
oligonucleotide. 
derive interfering RNA molecules, such as those described 
20 
herein. 
Single-stranded interfering RNAs can be synthesized 
chemically or by in vitro transcription or expressed endog- 25 
enously from vectors or expression cassettes as described 
herein in reference to double-stranded interfering RNAs. 5' 
Phosphate groups may be added via a kinase, or a 5' phos-
phate may be the result of nuclease cleavage of an RNA. A 
30 
hairpin interfering RNA is a single molecule (e.g., a single 
oligonucleotide chain) that comprises both the sense and 
antisense strands of an interfering RNA in a stem-loop or 
hairpin structure (e.g., a shRNA). For example, shRNAs can 
be expressed from DNA vectors in which the DNA oligo- 35 
nucleotides encoding a sense interfering RNA strand are 
linked to the DNA oligonucleotides encoding the reverse 
complementary antisense interfering RNA strand by a short 
spacer. If needed for the chosen expression vector, 3' terminal 
40 
T's and nucleotides forming restriction sites may be added. 
The resulting RNA transcript folds back onto itself to form a 
stem-loop structure. 
Nucleic acid sequences cited herein are written in a 5' to 3' 
direction unless indicated otherwise. The term "nucleic acid," 45 
as used herein, refers to either DNA or RNA or a modified 
form thereof comprising the purine or pyrimidine bases 
present in DNA (adenine "A," cytosine "C," guanine "G," 
thymine "T") or in RNA (adenine "A," cytosine "C," guanine 
50 
"G," uracil "U"). Interfering RNAs provided herein may 
comprise "T" bases, particularly at 3' ends, even though "T" 
bases do not naturally occur in RNA. "Nucleic acid" includes 
the terms "oligonucleotide" and "polynucleotide" and can 
refer to a single-stranded molecule or a double-stranded mo!- 55 
ecule. A double-stranded molecule is formed by Watson-
Crick base pairing betweenA and T bases, C and G bases, and 
between A and U bases. The strands of a double-stranded 
In a specific embodiment, the interfering RNA targeting 
LIMKl is AAGGACAAGAGGCTCAACTTCATCACTGA 
(SEQ ID NO. 1) 
It has been discovered that Aurora A induces phosphory-
lation of LIMKl at T508 and Aurora A kinase and LIMKl 
colocalize to the centrosomes. LIMKl also phosphorylates 
AurKA and knockdown ofLIMKl reduces the level of phos-
phorylated Aurora A. Knockdown of LIMKl further causes 
mislocalization of Aurora A kinase and disorganized spindle 
structure. The inventors work shows that Aurora A kinase and 
LIMKl are functionally cooperative during mitosis. 
As used herein, the term "effective amount" refers to the 
amount of a therapy that is sufficient to result in the preven-
tion of the development, recurrence, or onset of cancer and 
one or more symptoms thereof, to enhance or improve the 
prophylactic effect( s) of another therapy, reduce the severity, 
the duration of cancer, ameliorate one or more symptoms of 
cancer, prevent the advancement of cancer, cause regression 
of cancer, and/or enhance or improve the therapeutic effect(s) 
of another therapy. In an embodiment of the invention, the 
amount of a therapy is effective to achieve one, two, three or 
more of the following results following the administration of 
one, two, three or more therapies: (1) a stabilization, reduc-
tion or elimination of the cancer stem cell population; (2) a 
stabilization, reduction or elimination in the cancer cell popu-
lation; (3) a stabilization or reduction in the growth of a tumor 
or neoplasm; ( 4) an impairment in the formation of a tumor; 
(5) eradication, removal, or control of primary, regional and/ 
or metastatic cancer; ( 6) a reduction in mortality; (7) an 
increase in disease-free, relapse-free, progression-free, and/ 
or overall survival, duration, or rate; (8) an increase in the 
response rate, the durability of response, or number of 
patients who respond or are in remission; (9) a decrease in 
hospitalization rate; (10) a decrease in hospitalization 
lengths; (11) the size of the tumor is maintained and does not molecule may have partial, substantial or full complementa-
rity to each other and will form a duplex hybrid, the strength 
of bonding of which is dependent upon the nature and degree 
of complementarity of the sequence of bases. 
In certain embodiments, interfering RNA target sequences 
(e.g., siRNA target sequences) within a target mRNA 
sequence are selected using available design tools. Interfering 
RNAs corresponding to a LIMKl or AurKA target sequence 
60 increase or increases by less than 10%, preferably less than 
5%, preferably less than 4%, preferably less than 2%; (12) an 
increase in the number of patients in remission; (13) an 
increase in the length or duration of remission; (14) a decrease 
65 in the recurrence rate of cancer; (15) an increase in the time to 
recurrence of cancer; and (16) an amelioration of cancer-
related symptoms and/or quality of life. 
US 8,911,725 B2 
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As used herein, the terms "subject" and "patient" are used 
interchangeably. As used herein, the term "subject" refers to 
an animal, preferably a marmnal such as a non-primate (e.g., 
cows, pigs, horses, cats, dogs, rats etc.) and a primate (e.g., 
monkey and human), and most preferably a human. In some 
embodiments, the subject is a non-human animal such as a 
farm animal (e.g., a horse, pig, or cow) or a pet (e.g., a dog or 
cat). In a specific embodiment, the subject is an elderly 
human. In another embodiment, the subject is a human adult. 10 
In another embodiment, the subject is a human child. In yet 
another embodiment, the subject is a human infant. 
8 
response rate, the durability of response, or number of 
patients who respond or are in remission; (9) a decrease in 
hospitalization rate; (10) a decrease in hospitalization 
lengths; (11) the size of the tumor is maintained and does not 
increase or increases by less than 10%, preferably less than 
5%, preferably less than 4%, preferably less than 2%; (12) an 
increase in the number of patients in remission; (13) an 
increase in the length or duration of remission; (14) a decrease 
in the recurrence rate of cancer; (15) an increase in the time to 
recurrence of cancer; and (16) an amelioration of cancer-
related symptoms and/or quality of life. In certain embodi-
ments, such terms refer to a stabilization or reduction in the 
cancer stem cell population. In some embodiments, such 
15 terms refer to a stabilization or reduction in the growth of 
As used herein, the term "therapeutic agent" refers to any 
molecule, compound, and/or substance that is used for the 
purpose of treating and/or managing cancer. Examples of 
therapeutic agents include, but are not limited to, proteins, 
immunoglobulins (e.g., multi-specific Igs, single chain Igs, lg 
fragments, polyclonal antibodies and their fragments, mono-
clonal antibodies and their fragments), antibody conjugates 20 
or antibody fragment conjugates, peptides (e.g., peptide 
receptors, selectins ), binding proteins, chemospecific agents, 
chemotoxic agents (e.g., anti-cancer agents), radiation, che-
motherapy, anti-angiogenic agents, and small molecule 
drugs. Therapeutic agents may be a(n) anti-angiogenesis 25 
therapy, targeted therapy, radioimmunotherapy, small mol-
ecule therapy, biologic therapy, epigenetic therapy, toxin 
therapy, differentiation therapy, pro-drug activating enzyme 
therapy, antibody therapy, chemotherapy, radiation therapy, 
30 
hormonal therapy, immunotherapy, or protein therapy. 
cancer cells. In some embodiments, such terms refer to a 
stabilization or reduction in the cancer stem cell population 
and a reduction in the cancer cell population. In some 
embodiments, such terms refer to a stabilization or reduction 
in the growth and/or formation of a tumor. In some embodi-
ments, such terms refer to the eradication, removal, or control 
of primary, regional, or metastatic cancer (e.g., the minimi-
zation or delay of the spread of cancer). In some embodi-
ments, such terms refer to a reduction in mortality and/or an 
increase in survival rate of a patient population. In further 
embodiments, such terms refer to an increase in the response 
rate, the durability of response, or number of patients who 
respond or are in remission. In some embodiments, such 
terms refer to a decrease in hospitalization rate of a patient 
population and/or a decrease in hospitalization length for a 
patient population. 
The present invention also provides methods for treating 
35 cancer, the methods comprising administering to a patient 
(e.g., a human patient) in need thereof, a therapeutically 
As used herein, the terms "therapies" and "therapy" can 
refer to any method(s), composition(s), and/or agent(s) that 
can be used in the treatment of a cancer or one or more 
symptoms thereof. In certain embodiments, the terms 
"therapy" and "therapies" refer to chemotherapy, radiation 
therapy, radioimmunotherapy, hormonal therapy, targeted 
therapy, toxin therapy, pro-drug activating enzyme therapy, 
protein therapy, antibody therapy, small molecule therapy, 
40 
epigenetic therapy, demethylation therapy, histone deacety-
lase inhibitor therapy, differentiation therapy, antiangiogenic 
therapy, biological therapy including immunotherapy and/or 
other therapies useful in the treatment of a cancer or one or 
more symptoms thereof. 
effective regimen, the regimen comprising administering to 
the patient an inhibitor ofLIMKl and an inhibitor of AurKA, 
or an inhibitor that inhibits both LIMKl and AurKA, and 
optionally one or more additional therapies, said additional 
therapy not being compounds of the invention. The com-
pound of the invention and the additional therapy can be 
administered separately, concurrently, or sequentially. The 
45 combination of agents can act additively or synergistically. 
As used herein, the terms "treat", "treatment'', and "treat-
ing" in the context of the administration of a therapy to a 
subject refer to the reduction or inhibition of the progression 
and/or duration of cancer, the reduction or amelioration of the 
50 
severity of cancer, and/or the amelioration of one or more 
symptoms thereof resulting from the administration of one or 
more therapies. In a specific embodiment, a patient that is at 
a high risk for developing cancer is treated, i.e., a patient that 
has been diagnosed with aAurKa or Limkl positive precan- 55 
cerous lesion. In specific embodiments, such terms refer to 
one, two, or three or more results following the administration 
of one, two, three or more therapies: (1) a stabilization, reduc-
tion or elimination of the cancer stem cell population; (2) a 
stabilization, reduction or elimination in the cancer cell popu- 60 
lation; (3) a stabilization or reduction in the growth of a tumor 
or neoplasm; ( 4) an impairment in the formation of a tumor; 
( 5) eradication, removal, or control of primary, regional and/ 
or metastatic cancer; (6) a reduction in mortality; (7) an 65 
increase in disease-free, relapse-free, progression-free, and/ 
or overall survival, duration, or rate; (8) an increase in the 
PCT/USl0/35800; filed May 21, 2010 is cited herein in its 
entirety, and specifically for a teaching of the many additional 
therapies that may be administered in conjunction with 
LIMKl and/or AurKA inhibitors, or LIMKl/AurKA inhibi-
tors. U.S. Patent Publication 20100144783 is cited to for 
examples ofknownAurKA inhibitors, as well as an exposi-
tion on the number of cancers that may be treated according to 
the compounds and methods of the invention. U.S. Patent 
Publication 20100120771 is cited for AurKA inhibitors. 
Macdonald et al. Mo! CancerTher, 7:3490 (2008) is cited for 
teaching of LIMKl inhibitors and methodology for indenti-
fying such inhibitors, and U.S. App No. 12/706,218 is cited 
for teachings of LIMKl inhibitors. 
In general, compounds of the invention will be adminis-
tered in therapeutically effective amounts via any of the usual 
and acceptable modes known in the art, either singly or in 
combination with one or more therapeutic agents. A thera-
peutically effective amount may vary widely depending on 
the severity of the disease, the age and relative health of the 
subject, the potency of the compound used and other factors. 
US 8,911,725 B2 
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In general, satisfactory results are indicated to be obtained 
systemically at daily dosages of from about 0.03 to 2.5 mg/kg 
per body weight. An indicated daily dosage in the larger 
mammal, e.g. humans, is in the range from about 0.5 mg to 
about 1000 mg, conveniently administered, e.g. in divided 
doses up to four times a day or in retard form. Suitable unit 
dosage forms for oral administration comprise from ca. 1 to 
1000 mg active ingredient. In view of the inventor's discovery 
that LIMKl and AurKA inhibitors can work together syner-
gistically, this will allow dosages of each to be administered 10 
at lower levels than that required for usage of only one or the 
other classes of inhibitors. Synergy refers to the additive 
effect of using a dose of another inhibitor that is not achieved 
10 
antibodies. GAPDH expression was used as the loading con-
trol. BPHLCA pertains to BPH-1 cells expressing Flag-
tagged phosphomimic LIMKl (constitutively active), BPHV 
pertains to cellsBPH-1 cells transfected with the empty vec-
tor. Cells expressing the LIMKl phosphomic exhibited 
greater AurKA expression. 
Example 2 
FIG. 2 shows diagrams of full length (LIMK), constitu-
tively active phosphomimic (LIMKCA), LIM-domain only 
(LIMKLD), and kinase-domain only (LIMKKD) LIMKl 
by using the same dose of the same inhibitor. This is believed 
15 
constructs. These constructs were cloned into the pCMV14 
to lessen the possible toxicity that may be experienced with 
higher doses of a certain inhibitor. For example, if 100 mg is 
a determined daily dosage for only a AurKA inhibitor, then 
only 45 mg daily dosage of the AurKA inhibitor may be 
needed when 45-50 mg of a LIMKl inhibitor is administered 20 
in combination to achieve the same treatment effect. 
Pharmaceutical compositions of the invention can be 
administered by any number of routes including, but not 
limited to, oral, intravenous, intramuscular, intra-arterial, 
intramedullary, intrathecal, intraventricular, transdermal, 25 
subcutaneous, intraperitoneal, intranasal, parenteral, topical, 
sub lingual, or rectal means. Pharmaceutical compositions for 
oral administration can be formulated using pharmaceutically 
acceptable carriers well known in the art in dosages suitable 
for oral administration. Such carriers enable the pharmaceu- 30 
tical compositions to be formulated as tablets, pills, dragees, 
capsules, liquids, gels, syrups, slurries, suspensions, and the 
like, for ingestion by the patient. 
In addition to the active ingredients, these pharmaceutical 
35 
compositions can contain suitable pharmaceutically accept-
able carriers comprising excipients and auxiliaries which 
facilitate processing of the active compounds into prepara-
tions which can be used pharmaceutically. 
Pharmaceutical compositions comprising a compound of 40 
the present invention in free form or in a pharmaceutically 
acceptable salt form in association with at least one pharma-
ceutically acceptable carrier or diluent may be manufactured 
in a conventional marmer by mixing, granulating or coating 
methods. For example, oral compositions may be tablets or 45 
gelatin capsules comprising the active ingredient together 
vector used for expression in RWPEl cells. 
Example 3 
FIG. 3A shows the results of a Pull-down assay. Whole cell 
lysates from RWPE-1 cells transiently transfected with 
LIMK (RWPElL), LIMKLD (RWPElLLD), or LIMKKD 
(RWPElLKD) were incubated with recombinant His-tagged 
Aurora A bound to magnetic His-bind beads. Pull-down of 
LIMKl was detected by western blotting using anti-Flag 
antibodies. FIG. 3B shows that Aurora A interacts with 
LIMKl in vivo. FIG. 3B provides western blots of AurKA or 
Flag-tagged LIMKl in total cell extracts (Tot. extracts), 
FLAG immunoprecipitates, AurKA immunoprecipitates and 
rabbit IgG immunoprecipitates of total cell extracts prepared 
from BPHLCA and BPHV cells. An association between 
AurKA and LIMKl is demonstrated in these western blots. 
Example 4 
FIG. 4 shows that Aurora A phosphorylates inactive 
LIMKl in vitro. In vitro kinase assays were performed using 
recombinant GST-Aurora A kinase and GST-LIMKl. 32P 
incorporation was detected by autoradiography. B: Incuba-
tion of Aurora A with LIMKl resulted in phosphorylation of 
LIMKl at T508. Whole cell extracts from RWPE-1 cells 
transiently expressing LIMKl was treated with phosphatase 
and LIMKl was immunoprecipitated using anti-Flag anti-
bodies. Precipitates were then incubated in kinase assay 
buffer and cold ATP with or without recombinant AurKA. 
Phosphorylation at T508 was detected by western blotting 
with a) diluents, e.g., lactose, dextrose, sucrose, mannitol, 
sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, 
talcum, stearic acid, its magnesium or calcium salt and/or 
polyethyleneglycol; for tablets, together with c) binders, e.g., 
magnesium aluminum silicate, starch paste, gelatin, traga-
canth, methylcellulose, sodium carboxymethylcellulose and/ 
orpolyvinylpyrrolidone; and if desired, d) disintegrants, e.g., 
starches, agar, alginic acid or its sodium salt, or effervescent 
mixtures; and/ore) absorbents, colorants, flavors and sweet-
eners. Injectable compositions may be aqueous isotonic solu-
tions or suspensions, and suppositories may be prepared from 
fatty emulsions or suspensions. 
50 using phospho-specific LIMKl (T508) antibodies. 
EXAMPLES 
Example 1 
FIG. 1 Western blot analysis of the total cell extracts from 
BPHV or BPHLCA cells using anti-LIMKl or anti-AurKA 
Example 5 
FIG. 5 Dual label immunofluorescence analysis shows that 
55 LIMKl (red) and phospho AurKA (pAurKA) (green) colo-
calize to the centrosomes. This suggests that these two 
enzymes possess functional cooperativity with eachother. 
Example 6 
60 
FIG. 6 PC3 cells were transfected with LIMKl shRNA or 
control shRNA and the levels of LIMKl and pAurKA were 
detected by western blotting using anti-LIMKl or anti phos-
65 pho-AurKA antibodies. GAPDH was used as the loading 
control. The ratio of pAurKA to GAPDH levels was deter-
mined by densitometry (left panel). 
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Example 7 
FIG. 7 A: PC3 cells were transfected with either LIMKl or 
control shRNA. In control shRNA transfected cells, distinct 
localization of pAurKA (green) at the spindle poles (red) 
could be noted. In LIMKl shRNA treated cells, alpha-tubulin 
staining (red) showed disorganized spindle structure. Dif-
fused B: Knockdown of LIMKl increased the number of 
12 
with concentration of inhibitor. LIMKl knockdown appeared 
to increase sensitivity at lower inhibitor concentrations. 
At 48 hrs: 0.001 uM treatment resulted in LIMKl knock-
5 down wells having only 7 5% of the number of viable cells 
compared to control shRNA. While in the 0.1 uM treatment, 
LIMKl knockdown wells had 83% of the number of viable 
cells compared to the control shRNA. 
abnormal spindles in PC3 cells. PC3 cells were transfected 10 
with either LIMKl or control shRNA and spindle abnormali-
ties were quantified by counting 50 cells per treatment. 
When compared with untransfected PC3 cells treated with 
the vehicle (DMSO) LIMKl knockdown increased the sen-
sitivity of the cells to AurKA inhibitor at all concentrations at 
both 24 and 48 hr of treatment compared to untranfected PC3 
Example 8 
FIG. 8. Treatment with Aurora A kinase inhibitor 
MLN8237 resulted in Mislocaliation of phosphoLIMKl and 
phosphoAurK A: PC3 and RWPEl cells were treated with 
MLN8237 (0.01 uM) for 24 hr or the vehicle (DMSO) for 72 
hr. Immunofluorescence analysis showed that treatment with 
MLN8237 caused mislocalization of pAurKA (green) and 
improper spindle morphology (alpha-tubulin) (red). In addi-
15 cells only treated withAurKA inhibitor. 
In reviewing the detailed disclosure which follows, and the 
specification more generally, it should be borne in mind that 
all patents, patent applications, patent publications, technical 
20 publications, scientific publications, and other references ref-
erenced herein are hereby incorporated by reference in this 
application in order to more fully describe the state of the art 
to which the present invention pertains. 
tion, diffused staining and mislocalization of pLIMKl 
(green) and centrin (red) in the nucleus were noted. The 25 
vehicle control cells showed colocalization of pLIMKl with 
centrin to the centrosomes (red). Aurora A Inhibition 
Increased the Levels of phospho-Histone H3 suggesting 
mitotic arrest (B). Western blot analysis of nuclear extracts 
from PC3 cells treated with MLN8237 (0.01 uM). Y-tubulin 
staining was used as the loading control. Aurora A Inhibition 
Decreased Cell Survival (C). PC3 and RWPEl cells were 
treated with MLN8237 (0.01 uM) MLN8237 for 24, 48, and 
Reference to particular buffers, media, reagents, cells, cul-
ture conditions and the like, or to some subclass of same, is 
not intended to be limiting, but should be read to include all 
such related materials that one of ordinary skill in the art 
30 would recognize as being of interest or value in the particular 
context in which that discussion is presented. For example, it 
is often possible to substitute one buffer system or culture 
medium for another, such that a different but known way is 
35 
used to achieve the same goals as those to which the use of a 72 hr and cell viability was measured by MTT Assay. 
suggested method, material or composition is directed. 
Example 9 It is important to an understanding of the present invention 
to note that all technical and scientific terms used herein, 
Inhibition of LIMKl has a synergistic effect on treatment 
40 unless defined herein, are intended to have the same meaning withAurKA inhibitor MLN8237 
as commonly understood by one of ordinary skill in the art. 
Experimental Procedure: 
10 cm dishes were transiently transfected with 6 ug of 
LIMKl shRNA or control shRNA. 24 hrs post transfection, 
untransfected PC3 cells along with the transfected PC3 cells 
were seeded in 96 well plates in triplicate (5,000 cells/well). 
14 hrs after seeding, media was changed to MLN8237 con-
taining media, at concentrations of 0.001 uM, 0.01 uM, and 
0.1 uM. After 24 and 48 hours of inhibitor treatment, cell 
proliferation was measured using MTS assay. MTS reagent 
was added to each well and allowed to incubate for 3 hrs at 3 7° 
C. before reading absorbances. Absorbances were compared 
against controls. 
Results: 
Results for this example are shown in FIGS. 9-11. Untrans-
fected PC3 cells were most sensitive to 0.1 uM MLN823 7 at 
48 hrs. Inhibition seemed to be linear and increased with time. 
Untransfected PC3 cells were less sensitive than the trans-
fected cells. 
PC3 cells transfected with LIMKl shRNA experienced 
more sensitivity to MLN8237 than those cells transfected 
with the control shRNA. The number of viable cells in both 
transfected samples decreased with time and concentration of 
MLN8237, although the relative difference in viable cells 
between the control and LIMKl shRNA was not consistent 
The techniques employed herein are also those that are known 
to one of ordinary skill in the art, unless stated otherwise. For 
45 
purposes of more clearly facilitating an understanding the 
invention as disclosed and claimed herein, the following defi-
nitions are provided. 
While a number of embodiments of the present invention 
50 
have been shown and described herein in the present context, 
such embodiments are provided by way of example only, and 
not of limitation. Numerous variations, changes and substi-
tutions will occur to those of skilled in the art without mate-
rially departing from the invention herein. For example, the 
55 
present invention need not be limited to best mode disclosed 
herein, since other applications can equally benefit from the 
teachings of the present invention. Also, in the claims, means-
plus-function and step-plus-function clauses are intended to 
60 cover the structures and acts, respectively, described herein as 
performing the recited function and not only structural 
equivalents or act equivalents, but also equivalent structures 
or equivalent acts, respectively. Accordingly, all such modi-
65 fications are intended to be included within the scope of this 
invention as defined in the following claims, in accordance 
with relevant law as to their interpretation. 
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<160> NUMBER OF SEQ ID NOS, 1 
<210> SEQ ID NO 1 
<211> LENGTH, 29 
<212> TYPE, DNA 




<223> OTHER INFORMATION, Description of Unknown, LIMKl oligonucleotide 
<400> SEQUENCE, 1 
aaggacaaga ggctcaactt catcactga 
15 
What is claimed is: 
1. A method for treating prostate cancer in a subject, said 
method comprising administering a therapeutically effective 
amount of a LIM kinase 1 (LIMKl) inhibitor and an Aurora 
20 
Kinase A (AurKA) inhibitor to said subject, wherein said 
LIMKl inhibitor comprises an antibody that binds to LIMKl, 
and theAurKA inhibitor comprises MLN823 7 or an antibody 
that binds to AurKA. 
29 
3. The method of claim 1, further comprising administer-
ing an additional therapy to said subject prior to, during or 
subsequent to said administering of said LIMKl and AurKA 
inhibitors. 
2. The method of claim 1, wherein said LIMKl inhibitor is 
an antibody that bind to LIMKl and said AurKA inhibitor is 
an antibody that binds to AurKA. 
4. The method of claim 1, wherein said therapeutically 
effective amount of a LIMKl inhibitor and aAurKA inhibitor 
comprises a dosage of each that is effective for treatment of 
the cancer and which is lower than a dosage required to 
achieve the same level of treatment with only one of the 
25 inhibitors. 
* * * * * 
